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This study was conducted to determine if oral administration of the novel herbal medicine, KIOM-MA, and its Lactobacillus
acidophilus-fermented product, KIOM-MA128, has therapeutic properties for the treatment of atopic dermatitis (AD). Using AD-
inducedBALB/cmicebyOvalbuminandaluminumhydroxide,theeﬀectivenessofKIOM-MAandKIOM-MA128onADwaseval-
uated. Oral administration of KIOM-MA and KIOM-MA128 reduced major clinical signs of AD including erythema/darkening,
edema/papulation, excoriations, licheniﬁcation/prurigo, and dryness. Interestingly, KIOM-MA128 more signiﬁcantly improved
AD-related symptoms including decrease of IgE level in the plasma as well as reduction of scratching behavior, skin severity in
the AD BALB/c model. HPLC analysis showed the signiﬁcant changes in the constituent patterns between KIOM-MA and KIOM-
MA128. Our results suggest that both KIOM-MA and KIOM-MA128 have potential for therapeutic reagent for the treatment of
AD, and further, the eﬃcacy is signiﬁcantly enhanced by L. acidophilus fermentation via increases in its indicator molecule.
1.Introduction
Atopic dermatitis (AD) is a chronic inﬂammatory skin dis-
ease associated with cutaneous hyperreactivity to environ-
mentaltriggersthatareinnocuoustonormalnonatopicindi-
viduals [1]. Various studies have shown that atopic dermati-
tis has a complex etiology, with activation of multiple immu-
nological and inﬂammatory pathways [2]. In addition, sev-
eral studies have suggested that atopic dermatitis is the cuta-
neousmanifestationofasystemicdisorderthatalsogivesrise
toasthma,foodallergy,andallergicrhinitis[3,4].Thesecon-
ditions are all characterized by elevated serum IgE levels and
peripheral eosinophilia [5].
AD has long been considered a systemic disease for
which there are few satisfactory systemic therapies that do
not involve glucocorticoids [6]. In general, topically applied
medication of adequate potency, mainly corticosteroids, has
been standard for the vast majority of patients with AD [6].
Although intermittent use of topical corticosteroids is highly
eﬀective, the repeated use of steroids is not desirable due to
the systemic adverse eﬀects their long-term use can induce
[7, 8]. Accordingly, research has begun to identify steroid-
free alternative therapeutic agents with better eﬃcacy and
safety [9].
There has been increased interest in the use of tradi-
tional herbal medicine to develop new therapeutic agents
without a steroid for AD treatment [10]. In addition, recent
double-blind, placebo-controlled, crossover studies show
considerably eﬀective beneﬁts in managing clinical signs of
AD [11–14]. However, it is important to investigate the
active principles of the herbal medicines for quality control
and to determine their real therapeutic value in modern
pharmacology [15, 16]. Recent studies have suggested that
fermentation of herbal extracts may aﬀect the therapeutic
potential due to their increased absorptive eﬀect [17].2 Evidence-Based Complementary and Alternative Medicine
In this study, we report that newly formulated herbal
medicine KIOM-MA possesses strong antiatopic activity and
KIOM-MA128, fermented form by L. acidophilus,e x e r t s
more potent inhibitory eﬀect on AD.
2.MaterialsandMethods
2.1. Preparation and Fermentation of Novel Herbal Medicine.
Todevelopanovelherbalmedicineformulaforthetreatment
of AD, over 100 herbal medical formulas were tested by
the Center for Herbal Medicine Improvement Research at
the Korea Institute of Oriental Medicine. A novel herbal
medicine with antiatopic dermatitis eﬀects, KIOM-MA
(Glycyrrhizae Radix, Polygoni Cuspidati Rhizoma, Sophorae
Radix, Cnidii Rhizoma, Arctii Fructus, etc., Korean Patent
Application no. 10-2010-0093901, PCT/KR2010/007523),
was identiﬁed during this testing. Water extracts were then
prepared by steeping ﬁnely crushed herbs containing the
KIOM-MA medical formulation as described previously
[18], with some modiﬁcation. Brieﬂy, 1840.0g of the KIOM-
MA formula were placed in 18.4 L of distilled water and
boiled for about three hours at 115◦C. The extract was
then ﬁltered through a testing sieve (Aperture 500μma n d
150μm). All herbal plant materials were purchased from
Yeongcheon Oriental Herbal Market, Gyeongbuk Province,
Republic of Korea.
Fermentation was conducted using Lactobacillus acido-
philus (KFRI 128, KCTC 2182) donated from the Korea
Food Research Institute (KFRI). Brieﬂy, KIOM-MA water
extract was autoclaved for 5min, after which the pH was
neutralized using the addition of 1M NaOH. L. acidophyllus
was prepared by culturing in MRS broth at 37◦Cu n d e ra n ae -
robicconditions.Theinitialconcentrationofbacteriaranged
from 105 to 107 CFU/mL depending on the substrate.
KIOM-MA containing L. acidophyllus was fermented at
37◦C for 48h using MRS medium (10.0g/L Peptone,
10.0g/L Beef extract, 5.0g/L Yeast extract, 20.0g/L Glucose,
1.0mL/L Tween 80, 2.0g/L K2HPO4, 5.0g/L Sodium acetate,
2.0g/L Triammonium citrate, 0.2g/L MgSO4·7H2O, 0.2 g/L
MnSO4·4H2O, pH 6.2–6.6). The KIOM-MA128 was then
passed through a 60μm nylon net ﬁlter (Millipore, MA,
USA), precipitated overnight, lyophilized (supernatant), and
stored in desiccators at room temperature prior to use.
2.2. HPLC Analysis of KIOM-MA and KIOM-MA128. Active
principles separation was conducted using a reverse-phase
HPLC system consisting of an HPLC pump, as previously
described [19]. Fermented samples were monitored at
254nm and the area responses were integrated. The major
active compounds, isoﬂavones, were identiﬁed based on the
retention time and the PDA spectra of the pre- and postfer-
mentation herbal extracts were compared. Standard molecu-
les (liquiritin, nodakenin, icariin, and decursin) were pur-
chased from the Korea Food & Drug Administration. Glyc-
yrrhizin was purchased from Tokyo Chemical Industry
Co. (Tokyo, Japan). Decursinol angelate was purchased
from Natural Product Chemistry BioTech Inc. HPLC grade
Table 1: Mobile phase condition of chromatographic separation
(254nm).
Time
(min)
Water
(in 2% acetic acid)
Acetonitrile
(in 2% acetic acid)
Flow rate
(mL/min)
09 55 1
59 55 1
60 20 80 1
70 20 80 1
75 95 5 1
90 95 5 1
solutions, water, acetonitrile, and glacial acetic acid were
p u r c h a s e df r o mJ .T .B a k e rC o .( N J ,U S A ) .
2.3. Chromatographic Conditions. The high-performance
liquid chromatography (HPLC) data were obtained using an
Elite Lachrom analytical HPLC PDA system that included an
L-2130 binary HPLC pump, an L-2200 autosampler, a col-
umn oven (L-2350), and a diode array UV/VIS detector (L-
2455). The output signal of the detector was recorded using
the EZchrom Elite software for Hitachi. For separation of the
samples, an OptimaPak C 18 column (4.6mm × 250mm,
5μm ,R St e c h ,r e p u b l i co fR e p u b l i co fK o r e a )w a se m p l o y e d
and the PDA UV wavelength was 254nm. The mobile phase
was water and acetonitrile with a gradient elution containing
2% glacial acetic acid at a ﬂow rate of 1.0mL/min. The
column temperature was maintained at 40◦C( Table 1)a n d
the injection volume of the samples was 10μL.
2.4. Preparation of Standard Solutions and Samples. To pre-
pare the analytical samples, KIOM-MA and KIOM-MA128
(fermented KIOM-MA) powder were accurately weighed
and dissolved in 100% H2O at a concentration of 40mg/mL.
Prior to analysis, the sample was ﬁltered through a 0.45μm
ﬁlter.
2.5. Animals. 3-week-old male BALB/c mice were obtained
from Hanlim Laboratory Animals Co. (Hwasung, Kyunggi-
Do, Korea) and maintained for two weeks before the start of
the experiments. All animals were maintained on a standard
light-dark cycle at ambient temperature (23 ± 2◦C) and
humidity (55 ± 10%) with free access to chow pellets
and water. The experimental groups, which consisted of
5–7 animals per drug and dose, were selected by a ran-
domized schedule. Animal treatment and maintenance were
conducted in accordance with the Principle of Laboratory
Animal Care (NIH publication no. 85-23 revised in 1985)
and the Animal Care and Use Guidelines of Sahmyook
University, Republic of Korea.
2.6. Atopic Dermatitis Models. 5-week-old BALB/c mice
were anesthetized with ether and the dorsal skin was
then shaved with a clipper and a shaver one day before
experiments. The exposed dorsal region was treated with
Ovalbumin and aluminum hydroxide to induce AD. Mice
were randomly assigned to one of seven groups at the startEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: The HPLC chromatogram of KIOM-MA and KIOM-MA128 at 254nm.
of the experiment (n = 5): Group A, normal control; Group
B, AD control; Group C, KIOM-MA treatment (50mg/kg);
Group D, KIOM-MA treatment (100mg/kg); Group E,
KIOM-MA-128 treatment (50mg/kg); Group F, KIOM-MA-
128 treatment (100mg/kg); and Group G, dexamethasone
(1mg/kg). Following the last administration of KIOM-MA
or KIOM-MA128 on day 14, the mice were sacriﬁced and the
p l a s m aI g El e v e l sw e r em e a s u r e d .
2.7. Clinical Skin Severity Score. The dorsal skin of each
mouse was photographed before, during, and after KIOM-
MA or KIOM-MA128 treatment. The severity of AD-like
dorsal skin lesions was assessed once a day as follows:
dorsal lesions were evaluated for ﬁve symptoms, ery-
thema/darkening, edema/papulation, excoriations, licheniﬁ-
cation/prurigo,anddryness.Eachsymptomwasgradedfrom
0 to 3 (none, 0; mild, 1; moderate, 2; severe, 3). The clinical
skin score was deﬁned as the sum of the individual scores,
ranging from 0 to 15.
2.8.EstablishedLesionsandScratchingBehavior. Thescratch-
ing behavior was recorded on video once a day for 11 consec-
utivedays.Speciﬁcally,thenumberoftimesamousescratch-
edthedorsalskinlesionwithinaperiodof15minwascount-
ed. Because the average number of scratches in each mouse
varied daily, the scratching behavior was estimated as the
percentage of the control calculated from the mean value of
the no-treatment group.
2.9. Detection of Serologic IgE Concentration. Mice were sac-
riﬁced on 1, 3, 7, and 14 days after treatment of KIOM-MA
orKIOM-MA128,andcardiacbloodwascollectedfrommice
bythoracotomyintoEDTA-treatedtubes,afterwhichplasma
was separated by centrifugation at 3,000g for 10min at 4◦C
andstoredat −80◦C.TheplasmalevelsofIgEweremeasured
withELISAkits(R&DSystem,Boston,MA,USA)according
to the manufacturer’s instruction.
2.10.StatisticalAnalysis. Experimentalvaluesaregivenasthe
means ± SEM. The statistical diﬀerence was determined by a
two-sided Mann-Whitney U-test. A P<0.05 was considered
to indicate statistical signiﬁcance.
3. Results
3.1. HPLC Analysis. Six maker compounds of KIOM-
MA and KIOM-MA128 liquiritin (tR 22.1min), nodak-
enin (tR 23.4min), icariin (tR 31.1min), glycyrrhizin (tR
38.4min), decursin (tR 49.7min), and decursinol ange-
late (tR 50.1min) were identiﬁed by HPLC PDA anal-
ysis and comparison with standard compounds. Liquir-
itin (tR 22.1min), icariin (tR 31.1min), and glycyrrhizin4 Evidence-Based Complementary and Alternative Medicine
O
CH2OH
CH2OH
CH2OH
O
OH
OH
OH
OH
OH
OH
OH
HO
HO
HO
O
O
O
OO
OH
O
HO
O
O
Liquiritin
OCH3
Icariin
OH
OH
OH
OH
OH
HO
HO
O
O O
O
O
O
O
O
O O O
O
OO O
O
O
O O O
Glycyrrhizin
COOH
COOH
HOOC H
H
Nodakenin
Decursinol angelate Decursin
Figure 2: The chemical structure of six markers in KIOM-MA and KIOM-MA128.
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Figure 3: The eﬀect of KIOM-MA and KIOM-MA128 on atopic dermatitis-induced BALB/c mice. KIOM-MA and KIOM-MA128
signiﬁcantly mitigated ﬁve symptoms: erythema/darkening, edema/population, excoriations, licheniﬁcation/prurigo, and dryness at 7 days
after treatment.Evidence-Based Complementary and Alternative Medicine 5
Day 1
0
5
10
15
S
e
v
e
r
i
t
y
 
s
c
o
r
e
 
(
p
o
i
n
t
)
− 50 100 50 100 Dexa 1 mg
AD + +++++
Control 128 (mg/kg)
KIOM-MA
(a)
Day 3
0
5
10
15
S
e
v
e
r
i
t
y
 
s
c
o
r
e
 
(
p
o
i
n
t
)
− 50 100 50 100 Dexa 1 mg
AD + + + + + +
Control 128 (mg/kg)
KIOM-MA
(b)
Day 7
S
e
v
e
r
i
t
y
 
s
c
o
r
e
 
(
p
o
i
n
t
)
0
5
10
15
∗∗
∗ ∗
∗
KIOM-MA − 50 100 50 100 Dexa 1 mg
AD + + +++ +
Control 128 (mg/kg)
(c)
0
5
10
15
∗ ∗
∗∗
Day 14
S
e
v
e
r
i
t
y
 
s
c
o
r
e
 
(
p
o
i
n
t
)
− 50 100 50 100 Dexa 1 mg
A D ++++++
Control 128 (mg/kg)
KIOM-MA
(d)
Figure 4: The eﬀect of KIOM-MA and KIOM-MA128 on skin lesions. The improvement in skin lesions was evaluated based on the skin
severity score. The clinical skin severity was decreased in the KIOM-MA-treated group and much more improved in KIOM-MA128 after 7
days. Experimental values are given as the means ± SEM (n = 5). ∗P<0.05, ∗∗P<0.01, when compared with untreated group.
(tR 38.4min) were lower in KIOM-MA128 (fermented
KIOM-MA) following deglycosylation during fermentation.
Two peaks at retention times of 20.2 and 20.6 minutes
increased and one peak at 66.5 minutes appeared. The struc-
tures of the two increased constituents and the new constit-
uent were identiﬁed by chromatographic separation and
spectroscopic techniques (Figures 1 and 2).
3.2. KIOM-MA and KIOM-MA128 Exhibited Potent Anti-
atopic Eﬀect in BALB/c Mice Atopic Dermatitis Model. To
investigate the eﬀect of KIOM-MA and KIOM-MA128 on
AD, 50, or 100mg KIOM-MA, KIOM-MA128, 1mg dexam-
ethasone or a control (without KIOM additive) was orally
administered to ﬁve-week-old BALB/c mice, which have AD
induced by ovalbumin and aluminum hydroxide, once a
day for consecutive days. The atopic lesions of mice were
observed until 14 days after the ﬁrst treatment. From 7
days posttreatment, both KIOM-MA and KIOM-MA128
remarkably improved atopic symptoms comparable to con-
troldexamethasone,whichiswell-knownanti-inﬂammatory
reagent (Figure 3). Improved ﬁve symptoms contain ery-
thema/darkening, edema/papulation, excoriations, licheniﬁ-
cation/prurigo, and dryness.
3.3. The Eﬀect of KIOM-MA and KIOM-MA128 on Clinical
Skin Severity Score. Next, the improvement observed in
atopic skin lesions by KIOM-MA and KIOM-MA128 was
evaluated based on the skin severity score. The clinical skin
severity score was calculated from ﬁve major symptoms con-
sisting of symptomerythema/darkening, edema/papulation,
excoriations, licheniﬁcation/prurigo, and dryness. As shown
in Figure 4, skin severity score was signiﬁcantly decreased
in the KIOM-MA-treated group (P value = 0.0422 and
0.0487 at 50 and 10mg/kg, resp., compared with no-treated
group) and much more reduced in KIOM-MA128 (P value
= 0.0282 and 0.0120 at 50 and 10mg/kg, resp., compared6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: The eﬀect of KIOM-MA and KIOM-MA128 on scratching behavior. KIOM-MA or KIOM-MA128 was administered to the mice
as described in the Materials and Methods. Simultaneously, we counted the number of times the mice scratched skin lesions for 30min on
14 consecutive days. KIOM-MA and KIOM-MA128 caused a decrease in the scratching behavior, which was accompanied by improvement
of skin eruptions. ∗P<0.05, ∗∗P<0.01, when compared with untreated group.
with no-treated group) after 7 days. KIOM-MA and KIOM-
MA128 tended to decrease the skin severity score on day
5, and the scores of KIOM-MA and KIOM-MA128 were 5
and 3, respectively, compared with that of negative control
that was 10 on day 7 (Figure 4). The skin severity score of
dexamethasone was 3, same extent with KIOM-MA128.
On day 14, the scores of all groups were decreased, and on
day 21, KIOM-MA or dexamethasone-treated group had
the same clinical skin score as the no-treatment and the
control group (data not shown). Whether to determine if
the eﬀect of KIOM-MA or KIOM-MA128 depended on the
treatment dose, we administered diﬀerent doses (50 and
100mg/kg) of KIOM-MA. We found that both KIOM-MA
and KIOM-MA128 reduce the clinical skin severity score in
a dose-dependent manner on day 7 (Figure 4).
3.4.TheEﬀectofKIOM-MAandKIOM-MA128onScratching
Behavior. We next investigated the eﬀects of oral treatment
of KIOM-MA on the scratching behavior in the mice. As
represented in Figure 5, KIOM-MA reduced the number of
scratches and KIOM-MA128 exhibited more signiﬁcantly
decreased scratches on day 3 after the start of treatment,
which was accompanied by an improvement in the eruptions
(data not shown). On day 7 after treatment, the numbers
of scratching in atopic mice by treatment of KIOM-MA or
KIOM-MA128 were signiﬁcantly lower than control dexam-
ethasone. The diminished scratching behavior by treatment
of KIOM-MA (P value = 0.0197 and 0.02368 at 50 and
10mg/kg, resp., compared withno-treated group) or KIOM-
MA128 (P value = 0.0028 and 0.0013 at 50 and 10mg/kg,
resp., compared with no-treated group) was observed in
dose-dependent manner. An increase in the scratching
behavior of the mice was again observed immediately after
the discontinuation of the KIOM-MA treatment (data not
shown).
3.5. The Eﬀect of KIOM-MA and KIOM-MA128 on IgE Secre-
tion. Because AD is a type I IgE-mediated hypersensitivity
reactioncontributingtoimmunedysregulationanditsmajor
characteristics is hyperproduction of IgE, we examined theEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: The eﬀect of KIOM-MA and KIOM-MA128 on IgE secretion. A drastic decrease in the IgE levels was observed in KIOM-MA and
KIOM-MA128-treated mice. Values are the mean ± SEM (n = 5) ∗P<0.05, ∗∗P<0.01, when compared with the no-treatment group.
plasma IgE levels in the mice treated with KIOM-MA or
KIOM-MA128 and compared with that of control. Figure 6
shows that when the mice were induced to the AD, the plas-
ma IgE concentration was highly increased than control
group, and the IgE levels increased in the AD mice were
reduced with KIOM-MA (P value = 0.0090 and 0.0051 at
50 and 10mg/kg, resp., compared with no-treated group)
or KIOM-MA128 (P value = 0.0019 and 0.0023 at 50 and
10mg/kg, resp., compared with no-treated group) treatment
from day 7 after treatment. Consistent with skin severity and
starching behavior results, KIOM-MA128 exhibited much
stronger reducing eﬀect on IgE secretion in the plasma of AD
mice model (Figure 6).
4. Discussion
We investigated the eﬀects of KIOM-MA and its fermented
product, KIOM-MA128, in vitro and in vivo in an AD-like
animal model. The results demonstrated that KIOM-MA
eﬀectively reduced the clinical features and the index of AD-
like serum IgE level. Considering that AD is the most com-
mon skin disease, it is worth noting that the clinical recovery
from AD-like skin was more clearly seen based on macro-
graphy,scratchingcount,andseverityscoresinthetreatment
group. Hyperpigmentations and erythematous lesion erup-
tions also gradually improved signiﬁcantly in the treatment
group in a dose-dependent manner. The mice treated with8 Evidence-Based Complementary and Alternative Medicine
KIOM-MA or KIOM-MA128 did not show any clinical signs
in the skin after seven days of oral administration com-
parable to dexamethasone-treated group (positive control
group). The no-treatment group suﬀered continuously from
skin eruptions and skin injuries in response to scratching be-
havior after seven days. Furthermore, KIOM-MA and
KIOM-MA128 signiﬁcantly inhibited the AD clinical signs
in a dose-dependent manner. However, topical application
routes for atopic therapy are needed and are being tested
now. The pharmacodynamics and action mechanisms of
KIOM-MA and KIOM-MA128 are currently being investi-
gated in vitro with a focus on Th1/Th2 cytokines and related
chemokines.
S e v e r a lp r e v i o u ss t u d i e sh a v ee v a l u a t e dt h eu s eo fg l y -
cyrrhizin[20],liquiritin[21],anddecursin[21]forthetreat-
ment of AD, as well as nodakenin for anti-inﬂammatory ef-
fects [22], icariin for immunoregulatory eﬀects [23], and de-
cursinol angelate for blocking inﬂammatory activation [24].
Our results indicate that the high concentration of several
constituents including glycyrrhizin contained in the KIOM-
MA may be responsible for anti-inﬂammatory eﬀect of
KIOM-MA and KIOM-MA128. Interestingly, the KIOM-
MA128 fermented from KIOM-MA by L. acidophilus more
signiﬁcantly improved atopic symptoms. Fermentation, a
progress of decomposition of organic matter occurred by
L. acidophilus, generates various low molecular weight sub-
stances like aglycone from macromolecule including glyco-
side. This fact implies that active aglycone formed during
fermentation is more inﬁltrative than glycoside in vivo.
Aglycones may increase the skin or mucosal permeability,
thus, optimizing the physiological bioavailability in vivo.I n
addition, HPLC-DAD analysis of KIOM-MA and KIOM-
MA128 strongly implies that new constituents or increased
constituents may be involved in the antiallergic mechanism.
However, further studies should be performed to test these
hypotheses. Two increased peaks and one new peak are now
being subjected to isolate for the further study.
In summary, the pharmacological proﬁles of KIOM-MA
and KIOM-MA128 were as follows: the reduction of clini-
cal features and IgE production suggest that KIOM-MA
and KIOM-MA128 are eﬀective for the treatment of AD in
a dose-dependent manner. The oral administration route
may be useful for clinical improvement of AD, even though
topical application is generally thought to have more ther-
apeutic advantages. Bioconversion by fermentation signif-
icantly enhances the anti-inﬂammatory eﬀect of KIOM-
MA. Further studies are necessary to clarify the mechanisms
of KIOM-MA and KIOM-MA128 for the treatment of
AD. Nevertheless, our ﬁndings suggest that KIOM-MA and
KIOM-MA128,whichhasstrongereﬃcacy,couldbeapplica-
bletodeveloppotenttherapeuticreagentforthetreatmentof
AD.
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